Literature DB >> 16875934

The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features.

Gershon Y Locker1, Karen Kaul, David S Weinberg, Zoran Gatalica, Gordon Gong, Amy Peterman, Jane Lynch, Lucy Klatzco, Olufunmilayo I Olopade, Charles A Bomzer, Anna Newlin, Eileen Keenan, Mohammed Tajuddin, Joseph Knezetic, Stephanie Coronel, Henry T Lynch.   

Abstract

Colorectal cancer is common in Ashkenazi Jews. The I1307K APC mutation occurs in 6-7% of Ashkenazi Jews and increases the risk of colorectal cancer. This study aimed to describe the clinical, pathologic and epidemiologic features of colorectal cancer in I1307K carriers to determine whether there were any features which might warrant individual screening for the mutation. In all, 215 Ashkenazi Jews with a personal history of colorectal cancer were enrolled. Clinical and family history, pathology reports, and slides were obtained and blood drawn for I1307K determination. The presence of the mutation was determined by PCR from white blood cell DNA. Colorectal cancer pathology slides were read in a blinded fashion. Of the 215 enrolled patients, 26 (12.1%) tested positive for I1307K. There was no difference in the pathologic features between colorectal cancers in Ashkenazi carriers compared to noncarriers. There was no difference in the age at diagnosis or history of second or other primaries. Carriers had an increased likelihood of having a first-degree relative with colorectal cancer (50%) compared to noncarriers (28%, P < 0.04). We could find no distinguishing feature other than family history that characterizes I1307K positive colorectal cancers. We could find no group of Ashkenazi Jews with colorectal cancer for whom screening for I1307K would be clinically useful.

Entities:  

Mesh:

Year:  2006        PMID: 16875934     DOI: 10.1016/j.cancergencyto.2006.03.007

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

1.  Cancer genetic testing panels for inherited cancer susceptibility: the clinical experience of a large adult genetics practice.

Authors:  Christina G Selkirk; Kristen J Vogel; Anna C Newlin; Scott M Weissman; Shelly M Weiss; Chi-Hsiung Wang; Peter J Hulick
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

2.  Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.

Authors:  Deborah T Blumenthal; Addie Dvir; Alexander Lossos; Tzahala Tzuk-Shina; Tzach Lior; Dror Limon; Shlomit Yust-Katz; Alejandro Lokiec; Zvi Ram; Jeffrey S Ross; Siraj M Ali; Roi Yair; Lior Soussan-Gutman; Felix Bokstein
Journal:  J Neurooncol       Date:  2016-08-16       Impact factor: 4.130

3.  Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome.

Authors:  L Raskin; F Schwenter; M Freytsis; M Tischkowitz; N Wong; G Chong; S A Narod; D A Levine; F Bogomolniy; M Aronson; S N Thibodeau; K S Hunt; G Rennert; S Gallinger; S B Gruber; W D Foulkes
Journal:  Clin Genet       Date:  2010-12-14       Impact factor: 4.438

4.  Roles and responsibilities of a medical geneticist.

Authors:  Wendy S Rubinstein
Journal:  Fam Cancer       Date:  2007-07-12       Impact factor: 2.375

Review 5.  Genetics, cytogenetics, and epigenetics of colorectal cancer.

Authors:  Lucia Migliore; Francesca Migheli; Roberto Spisni; Fabio Coppedè
Journal:  J Biomed Biotechnol       Date:  2011-02-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.